A Phase II, Multi-Centre, Placebo-Controlled, Randomised Study of the Safety, Pharmacokinetics and Antiviral Activity of BIT225 in Combination with Pegylated Interferon alfa-2b and Ribavirin in Patients with Hepatitis C Virus Infection.

Trial Profile

A Phase II, Multi-Centre, Placebo-Controlled, Randomised Study of the Safety, Pharmacokinetics and Antiviral Activity of BIT225 in Combination with Pegylated Interferon alfa-2b and Ribavirin in Patients with Hepatitis C Virus Infection.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2016

At a glance

  • Drugs BIT 225 (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Biotron
  • Most Recent Events

    • 04 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 30 Sep 2015 Updated interim results published in the Media Release.
    • 06 Jul 2015 Interim results published in the Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top